Aerie Pharmaceuticals, Inc.

The US Food and Drug Administration’s prescription drug user fee goal date calendar for May may be overshadowed by the 31 May goal date for Moderna ’s next-generation COVID-19 vaccine, given a resurg

Biopharma Acquisitions Biopharma merger and acquisition value for the third quarter of 2022 reached $15.4bn from 41 transactions, 21 of which had disclosed values. Four M&A transactions hit or exceede

After its spin-out from Novartis AG in 2019, ophthalmology specialist Alcon Inc. has steadily expanded its pharmaceutical portfolio and formed a dedicated sales channel to focus specifically on ey

Ophthalmology specialist Alcon Inc. will buy Aerie Pharmaceuticals, Inc. for roughly $770m, gaining two commercial products for glaucoma, a Phase III drug candidate for dry eye disease and other e